Drug Profile
Miglustat - Actelion Pharmaceuticals
Alternative Names: AT2221; Brazaves; NB-DNJ; OGT 918; OXAIDS; SC 48334; ZavescaLatest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Oxford Glycobiology Institute
- Developer Actelion Pharmaceuticals; National Taiwan University; Teva Pharmaceutical Industries; United Therapeutics Corporation
- Class Alkaloids; Imino pyranoses; Small molecules
- Mechanism of Action Alpha-glucosidase inhibitors; Glucosylceramide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gaucher's disease type I; Niemann-Pick disease type C
- Phase II Cystic fibrosis; Gaucher's disease type III
- No development reported Hepatitis C
- Discontinued HIV infections; Tay-Sachs disease
Most Recent Events
- 10 Apr 2019 Actelion Pharmaceuticals plans a phase IV trial for Niemann-Pick diseases (In children, In adolescents, In adults, In the elderly) in China (PO, Capsule) in July 2019 (NCT03910621)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals